Axonics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported sales was USD 116.19 million compared to USD 93.1 million a year ago. Net loss was USD 0.021 million compared to net income of USD 3.93 million a year ago. For the nine months, sales was USD 322.17 million compared to USD 256.64 million a year ago. Net loss was USD 12.23 million compared to USD 12.66 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.26 a year ago. Diluted loss per share from continuing operations was USD 0.24 compared to USD 0.26 a year ago.
Axonics is a California-based medical device company that develops and distributes neurosimulator products for the treatment of bladder and bowel dysfunction.